
PainReform Ltd. PRFX
€ 2.27
-0.37%
Geschäftsbericht 2025
hinzugefügt 11.04.2026
PainReform Ltd. Gesamtes Eigenkapital 2011-2026 | PRFX
Gesamtes Eigenkapital Jährlich PainReform Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.54 M | 1.82 M | 7.24 M | 11 M | 18.1 M | 16.6 M | -12.2 M | -11.1 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 18.1 M | -12.2 M | 5 M |
Gesamtes Eigenkapital Vierteljährlich PainReform Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 18.1 M | - | 19 M | - | 16.6 M | - | -14.2 M | - | -12.2 M | - | -11.5 M | - | -11.1 M | - | - | - | -10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 19 M | -14.2 M | -688 K |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
Akari Therapeutics, Plc
AKTX
|
28.3 M | $ 5.12 | 11.55 % | $ 345 B | ||
|
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.97 | 6.43 % | $ 9.55 B | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 320.13 | -3.98 % | $ 41.9 B | ||
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | ||
|
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
53.5 M | $ 7.66 | 3.23 % | $ 75.7 M | ||
|
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-9.98 M | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 21.81 | 0.6 % | $ 1.02 B | ||
|
Burford Capital Limited
BUR
|
1.7 B | $ 4.67 | -1.37 % | $ 766 M | ||
|
CymaBay Therapeutics
CBAY
|
292 M | - | - | $ 3.45 B | ||
|
BioNTech SE
BNTX
|
1.37 B | $ 102.12 | 2.66 % | $ 27.2 B | ||
|
Cabaletta Bio
CABA
|
112 M | $ 3.52 | 3.53 % | $ 354 M | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.08 | -4.94 % | $ 5.07 M | ||
|
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
-11.9 M | - | -5.16 % | $ 5.39 M | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
32.6 M | $ 1.35 | -12.9 % | $ 347 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.26 | 0.47 % | $ 456 M | ||
|
Arcutis Biotherapeutics
ARQT
|
189 M | $ 24.19 | -1.59 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.61 | 8.05 % | $ 428 M | ||
|
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
29.6 M | - | -16.75 % | $ 25.8 M | ||
|
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | ||
|
Clearside Biomedical
CLSD
|
-15.9 M | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
527 M | $ 33.86 | -0.03 % | $ 2.25 B | ||
|
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | ||
|
CNS Pharmaceuticals
CNSP
|
4.52 M | $ 2.75 | - | $ 1.22 M |